Advertisement
Advertisement


News

FDA Approved Changes to the Genvoya Label

September 7, 2016

Recently, FDA approved changes to the GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), 150/150/200/10 mg fixed-dose combination tablet product labeling. The following main updates were made:

1. Longer term safety, efficacy and resistance data from 96 weeks of treatment from Study GS-US-292 0104 & GS-US-292 0111 (antiretroviral therapy (ART)-naive adults).

  • GS-US-292-0104 entitled "A Phase 3, Randomized, Double-Blind Study to EvaluateThe Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1Positive, Antiretroviral Treatment- Naïve Adults"
  • GS-US-292-0111 entitled "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment- Naïve Adults"

2. Drug-drug interactions between Genvoya and the following co-administrated drugs in healthy subjects 1) ledipasvir/sofosbuvir fixed-dose combination tablet; and 2) sofosbuvir/velpatasvir fixed-dose combination tablet. No clinically significant drug interactions were observed when GENVOYA is combined with ledipasvir or velpatasvir.

3. In addition, the content of labeling was updated to include content and format revisions to the "Use in Specific Populations (Sections 8.1 and 8.2)" related to the Pregnancy and Lactation Labeling Rule (PLLR).

The updated label will soon be available drugs@fda or DailyMed.




This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.